Genomics firm Helicos gets delisted

The Cambridge, MA based genomics company Helicos Biosciences has been delisted from the NASDAQ. The company received a delisting notice in April. Shortly after, Helicos cut its work force in half, laying off 40 people to focus on its diagnostics business, but in the months since it has been unable to goose its stock above the $1 mark. Article

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.